↓ Skip to main content

Renal sympathetic denervation versus antiarrhythmic drugs for drug-resistant hypertension and symptomatic atrial fibrillation (RSDforAF) trial: study protocol for a randomized controlled trial

Overview of attention for article published in Trials, June 2013
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
81 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Renal sympathetic denervation versus antiarrhythmic drugs for drug-resistant hypertension and symptomatic atrial fibrillation (RSDforAF) trial: study protocol for a randomized controlled trial
Published in
Trials, June 2013
DOI 10.1186/1745-6215-14-168
Pubmed ID
Authors

Min Qiu, Yuehui Yin, Qijun Shan

Abstract

BACKGROUND: Recently, catheter-based renal sympathetic denervation (RSD) has been verified to be safely used to substantially reduce the levels of blood pressure, left ventricular hypertrophy, sleep apnea severity and norepinephrine spillover, and improve glucose tolerance. All these pathological changes are recognized as independent risk factors for the development and recurrence of atrial fibrillation (AF). A randomized, single-blind, parallel-control, multicenter clinical trial is being conducted to compare RSD with antiarrhythmic drugs (AAD) in patients with drug-resistant hypertension and symptomatic AF (RSDforAF trial).Methods/design: Patients with drug-resistant hypertension and symptomatic AF will be randomized to RSD and the drug treatment groups. Patients will be followed for 12 months until study closure. Up to 200 patients may be enrolled in six medical centers in China. The primary objective is to study the effects of RSD on AF burden and blood pressure in patients with hypertension and symptomatic AF. DISCUSSION: RSDforAF trial will test the hypothesis that RSD is superior to AAD in reducing AF burden and blood pressure in patients with drug-resistant hypertension and symptomatic AF.Trial registration: The trial is registered at www.clinicaltrials.gov, registry number: NCT01713270.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 80 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 16 20%
Student > Postgraduate 11 14%
Researcher 10 12%
Other 7 9%
Student > Bachelor 7 9%
Other 11 14%
Unknown 19 23%
Readers by discipline Count As %
Medicine and Dentistry 41 51%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Biochemistry, Genetics and Molecular Biology 4 5%
Agricultural and Biological Sciences 3 4%
Economics, Econometrics and Finance 2 2%
Other 6 7%
Unknown 21 26%